Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

Ранг среди акций #3111
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Цена акции
$91.51
Рыночная капитализация
$5.75B
Изменение (1 день)
6.72%
Изменение (1 год)
549.01%
Страна
US
Торговля Kodiak Sciences Inc. (KOD)

Категория

Healthcare
EPS для Kodiak Sciences Inc. (KOD)
EPS по состоянию на June 2026 TTM: $-4.19
Согласно последним финансовым отчетам и цене акций Kodiak Sciences Inc., текущий EPS компании (TTM) составляет $-4.19. В конце 2023 EPS компании составлял $-4.97, меньше, чем показателю 2022 года, равному $-6.39.
История EPS компании Kodiak Sciences Inc. с 2016 по 2026
EPS на конец каждого года
Год EPS Изменить
2026 (TTM) $-4.19 25.07%
2024 $-3.35 -32.60%
2023 $-4.97 -22.22%
2022 $-6.39 23.84%
2021 $-5.16 77.32%
2020 $-2.91 136.59%
2019 $-1.23 6.03%
2018 $-1.16 10.48%
2017 $-1.05 -54.35%
2016 $-2.30 0.00%
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -513.37%
US
$-7.98 90.45%
US
$-5.29 26.25%
AU
- -
CH
$27.74 -762.05%
NL